Research programme: adenovirus infection therapeutics - AiCuris
Latest Information Update: 18 Jul 2023
At a glance
- Originator AiCuris
- Class Antivirals; Eye disorder therapies; Small molecules
- Mechanism of Action Undefined mechanism
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Preclinical Adenovirus infections; Keratoconjunctivitis
Most Recent Events
- 17 Jul 2023 Research programme: adenovirus infection therapeutics - AiCuris is available for licensing as of 17 Jul 2023. https://www.aicuris.com/38/Partnering.htm
- 17 Jul 2023 Preclinical trials in Adenovirus infections in Germany (unspecified route) (AiCuris pipeline, July 2023)
- 17 Jul 2023 Preclinical trials in Keratoconjunctivitis in Germany (Topical) (AiCuris pipeline, July 2023)